Robert James Email & Phone Number

Sixth Element Capital is a new fund management business, which has been established to identify investment gaps initially in healthcare markets and to implement novel solutions to bring finance and innovation together. In drug development, the challenge of translating academic opportunities into commercial products has become more acute in recent years. A.

I was a Founding Partner in DFJEsprit when it was created through a merger between Prelude Ventures, one of the oldest European early stage technology VCs and the private equity team from Cazenove.

I was a partner at Prelude Ventures for 8 years making investments in early stage biotechnology and medical technology companies. I made investments in companies such as DNA Research Innovations, Oxford Immunotec, Kiadis Pharmaceuticals.

I was the third hire at CRT (whilst I was there it was called CRCT) working on the commercial exploitation of intellectual property created by CRUK funded scientists. This was through establishing licensing or collaborative arrangements with pharma or biotech companies or starting up companies. I was part of the team that licensed Temodal to Schering Plough.

Phd, Signal Transduction Pathways

Bsc, Genetics